Renal disease and digoxin immunoassays.

Renal disease and digoxin immunoassays.

Daunorubicin (Cerubidin) No No No No Dacarbazine (DTIC) Yes No No No Vindesine (Eldisine) Yes No No No 5-Fluorouracil (Fluoro-uracil) No No No No Mithramycin (Mithracin) No No No No Mitomvcin (mitomycin C, Kyowa) No No No No Mustine hydrochloride (Mustine) Yes No No No CyclophosphaITiide (Endoxan-Asta) No No No No Doxorubicin (Adriamycin) Yes No Yes Yes Cytarabine (Cytosar-U) No No No No Actino...

Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays.

tients. Clin Chem 1995;41:256–63. 9. Niederwieser G, Bonelli RM, Brunner D, Neubauer M, Buchinger W, Reisecker F, et al. Diagnostic accuracy of an agarose gel electrophoretic method in multiple sclerosis. Clin Chem 2001;47:144. 10. Cavuoti D, Baskin L, Jialal I. Detection of oligoclonal bands in cerebrospinal fluid by immunofixation electrophoresis. Am J Clin Pathol 1998;109:585–8. 11. Richard ...

Digoxin use increases mortality in end-stage renal disease.

Digoxin determination in the uremic patient: three immunoassays compared.

between CA-19-9 concentrations in blood and whether or not patients were taking supplements. Thus, cystic fibrosis is one of the first benign diseases shown to be associated with high CA-19-9 concentrations in blood. The origin of CA-19-9 in these patients instill unknown. it is unlikely to be derived from the pancreas because patients with pancreatitis reportedly have low concentrations of thi...

Methods for eliminating interferences in digoxin immunoassays caused by digoxin-like factors.

Endogenous, circulating digoxin-like immunoreactive factors (DLIF) are known to cross react with many antisera used in digoxin assays, complicating the quantification of serum digoxin. We have explored ways to decrease or remove the interference from DLIF in such assays. Prolonging the assay incubation from 30 to 60 min decreased apparent digoxin concentrations (attributable to DLIF) by an aver...